Biogen (BIIB) Stock Forecast, Price & News

Biogen (NASDAQ:BIIB) Frequently Asked Questions

Is Biogen a buy right now?

32 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 16 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Biogen stock.
View analyst ratings for Biogen or view top-rated stocks.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022.
View our earnings forecast for Biogen.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) issued its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported $3.62 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.41 by $0.79. The biotechnology company earned $2.53 billion during the quarter, compared to analysts' expectations of $2.50 billion. Biogen had a trailing twelve-month return on equity of 23.46% and a net margin of 13.40%. Biogen's revenue for the quarter was down 6.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.34 EPS.
View Biogen's earnings history.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $14.25-$16.00 for the period, compared to the consensus EPS estimate of $15.44. The company issued revenue guidance of $9.70 billion-$10.00 billion, compared to the consensus revenue estimate of $9.87 billion.

What price target have analysts set for BIIB?

32 analysts have issued twelve-month target prices for Biogen's shares. Their forecasts range from $185.00 to $500.00. On average, they expect Biogen's stock price to reach $275.47 in the next twelve months. This suggests a possible upside of 34.1% from the stock's current price.
View analysts' price targets for Biogen or view top-rated stocks among Wall Street analysts.

Who are Biogen's key executives?

Biogen's management team includes the following people:

• Mr. Michel Vounatsos, CEO & Director (Age 60, Pay $4.51M) (LinkedIn Profile)
• Mr. Michael R. McDonnell CPA, Exec. VP & CFO (Age 58, Pay $1.56M)
• Ms. Susan H. Alexander Esq., Exec. VP, Chief Legal Officer & Sec. (Age 65, Pay $1.58M)
• Mr. Chirfi Guindo, Exec. VP and Head of Global Product Strategy & Commercialization (Age 56, Pay $1.17M)
• Ms. Robin C. Kramer, Sr. VP & Chief Accounting Officer (Age 56)
• Ms. Nicole Murphy, Head of Pharmaceutical Operations & Technology
• Mr. Michael Hencke, Head of Investor Relations
• Ms. Natacha Gassenbach, Chief Communication Officer & Head of Corp. Affairs
• Dr. Ginger Gregory, Exec. VP & Chief HR Officer (Age 54)
• Dr. Anabella Villalobos Ph.D., Head of Biotherapeutics & Medicinal Sciences

What is Michel Vounatsos' approval rating as Biogen's CEO?

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

Who are some of Biogen's key competitors?

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Exact Sciences (EXAS), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all of BIIB's competitors.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by many different institutional and retail investors. Top institutional investors include Primecap Management Co. CA (10.81%), BlackRock Inc. (9.64%), Vanguard Group Inc. (8.00%), State Street Corp (4.92%), Wellington Management Group LLP (4.27%) and Clearbridge Investments LLC (1.71%). Company insiders that own Biogen stock include Alfred Sandrock, Brian S Posner and Michel Vounatsos.
View institutional ownership trends for Biogen.

Which major investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Bellevue Group AG, Citigroup Inc., Invesco Ltd., Group One Trading L.P., PEAK6 Investments LLC, UBS Group AG, IMC Chicago LLC, and Canada Pension Plan Investment Board. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Brian S Posner.
View insider buying and selling activity for Biogen or view top insider-selling stocks.

Which major investors are buying Biogen stock?

BIIB stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., BlackRock Inc., Pacer Advisors Inc., Assenagon Asset Management S.A., State Street Corp, Vanguard Group Inc., Retirement Systems of Alabama, and Federated Hermes Inc..
View insider buying and selling activity for Biogen or or view top insider-buying stocks.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $205.42.

How much money does Biogen make?

Biogen has a market capitalization of $30.08 billion and generates $10.98 billion in revenue each year. The biotechnology company earns $1.56 billion in net income (profit) each year or $9.769990 on an earnings per share basis.

How many employees does Biogen have?

Biogen employs 9,610 workers across the globe.

Does Biogen have any subsidiaries?

The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.

When was Biogen founded?

Biogen was founded in 1978.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (617) 679-2000, via email at [email protected], or via fax at 617-679-2617.